: iStockAnalyst.com Symbols Feed

On Picking Stocks And Market Corrections

Wed, 26 Aug 2009 04:47:18 GMT

Hello Friends! Thanks so much for stopping by and visiting my blog, Stock Picks Bob's Advice! As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website. I set out tonight to write up an entry about a suitable stock to add to my blog. But nothing seemed right. I scanned through the list of the top % gainers, my usual starting place, but there were few stocks over $10.[More...]

Switching From Haemonetics (NYSE: HAE) Into Oshkosh (NYSE: OSK) "Trading Transparency"

Wed, 05 Aug 2009 13:17:00 GMT

Hello Friends! Thanks so much for stopping by and visiting my blog, Stock Picks Bob's Advice! As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website. As is part of my blogging, I wanted to share with you a 'swap' I made out of my position in Haemonetics (HAE) and into Oshkosh (OSK). Both of these are mid cap stocks but that is where the similarity ends. On Monday, August 3, 2009, I sold my 50 shares of Haemonetics (HAE) at $55.08 after what I viewed as both technical weakness[More...]

Haemonetics (HAE) : Trading Transparency

Tue, 05 May 2009 13:08:23 GMT

Hello Friends! Thanks so much for stopping by and visiting my blog, Stock Picks Bob's Advice! As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website. Today Haemonetics (HAE), one of the six holdings in my trading account, announced 4th quarter results. Revenue for the quarter rose 10% to $152.4 million. Excluding items the company earned $.65/share. Analysts had been expecting $.63/share so the company beat[More...]

Medical Devices - Industry Outlook

Fri, 10 Apr 2009 00:07:39 GMT

Since the beginning of the global economic crisis, medical device stocks have fared no better than the overall market with both down just over 40% since September 1 2008 on a market weighted basis. We continue to recommend that investors focus on companies providing life-sustaining products. These should remain insulated from the current economic crisis as target patients are unable to forego procedures. The recent slide in the market has left many strong companies looking very attractive. In the coming year, investors should allocate funds to companies with high earnings quality profiles. We recommend companies with the following characteristics: Size - (1) Larger companies will find it easier to survive any future liquidity issues and acquire new technologies at cents on the dollar Scope - (1) Companies providing life-sustaining products should remain insulated from the current[More...]

Trading FDA Decisions: 14 Extreme Trades

Wed, 11 Mar 2009 16:25:00 GMT

Below is a summary of companies from the BioMedReports.com FDA Decision Date Calendar which have market caps below $200M, making them ideal candidates for extreme stock price volatility trades as their decision dates become imminent. Dyax Corp. (DYAX) secured a narrow approval from a FDA Advisory Panel in early February (with a 6-5-2 vote) for its Kalbitor (ecallantide or DX-88) BLA with a PDUFA date of 3/23/09, which is designated for priority review in the treatment of acute attacks of hereditary angioedema (HAE is a rare disorder marked by severe swelling which can be fatal if the throat area is involved). The panel debated the need for an effective treatment for this rare, potentially dangerous condition against the 3% higher incidence of allergic reactions (13% versus 10%) in patients taking[More...]

FDA Calendar: A Weekly Update

Fri, 05 Dec 2008 23:01:00 GMT

The accompanying table (click to enlarge) presents an updated calendar of 73 expected FDA decision dates as part of the ETF Innovators (ETFI) New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week. 1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE), which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standard 10-month review target decision date = 10/1/09. 2.) Questcor Pharma (QCOR) – Re-submitted a sNDA on 12/2/08 to expand the use of H.P. Acthar[More...]

Emerging Biotech & Pharma Index: 36 More Cos.

Mon, 24 Nov 2008 05:35:00 GMT

The accompanying table (click to enlarge or download) includes the 36 remaining companies in the ETF Innovators (ETFI) Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff. However, several of the companies included in the remaining group of 36 have been in the news recently due to [More...]

Med Devices to Prove Recession Resistant

Tue, 28 Oct 2008 12:58:00 GMT

Though most analysts in their respective industries have been taking a more conservative approach to rating companies under their coverage, Zacks senior medical devices & supplies analyst Christopher Titus, CFA has been upgrading several names that he follows recently. To find out what, we asked him a series of questions about his industry. Despite a difficult environment for the markets and the U.S. economy, you are growing more bullish on the medical devices sector, is that true? True enough. Medical device stocks should provide investors with opportunities for solid, lower-risk returns over the coming six to twelve months. The recent slide in the market has left many strong companies looking very attractive. In the coming year, investors should allocate funds to companies with high earnings quality[More...]

Haemonetics And BE Aerospace

Tue, 28 Oct 2008 06:07:00 GMT

Hello Friends! Thanks so much for stopping by and visiting my blog, Stock Picks Bob's Advice! As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any decisions based on information on this website. I must be a glutton for punishment. After having sold two of my positions earlier today, I started looking at the lists of top % gainers to see if I could find any new candidates for the portfolio, utilizing my new reduced investment size strategy I discussed in the previous entry. The first stock that[More...]

Best Perfomers Over Last Quarter

Mon, 06 Oct 2008 06:14:00 GMT

It is a moot point looking at weekly winners this week; just a handful of stocks moving up led by such growers as Campbell Soup (CPB) aka "people will still need to eat soup if nothing else" trade. So instead I am going to look at the best and worst performers the past 3 months. In this post we have every stock over $1.25B in market cap returning 15%+ (115 stocks) Now keep in mind the data is a bit misleading because 3 months ago at this time we were in the throes of another painful correction, in a series of step ladders down. About 90 days ago Fannie and Freddie and Lehman were falling off a cliff, and we were just over a week away from Hank Paulson going to Congress to create a plan to backup Fannie/Freddie. So this was a "bottom" and the financials rallied hard for the next 6-7 weeks - Fannie/Freddie of course were officially taken over within 2 months from that point.[More...]

THE OUTLOOK ; February 2009

Mon, 02 Feb 2009 23:50:00 GMT

EARNINGS: Bay State companies First Marblehead Corp., Haemonetics Corp., Hologic Inc. and Unica Corp. post financial reports.
The Institute for Supply Management's factory index for January is expected to hit its lowest level since 1980.
Automakers report U.S. auto sales for January.

: iStockAnalyst.com Symbols Feed

On Picking Stocks And Market Corrections

Switching From Haemonetics (NYSE: HAE) Into Oshkosh (NYSE: OSK) "Trading Transparency"

Haemonetics (HAE) : Trading Transparency

Medical Devices - Industry Outlook

Trading FDA Decisions: 14 Extreme Trades

FDA Calendar: A Weekly Update

Emerging Biotech & Pharma Index: 36 More Cos.

Med Devices to Prove Recession Resistant

Haemonetics And BE Aerospace

Best Perfomers Over Last Quarter

THE OUTLOOK ; February 2009

Myriad Genetics Elects Louise Phanstiel and Lawrence Best to Its Board of Directors

Haemacure announces its presentation at the Rodman & Renshaw 11th Annual Healthcare Conference

Haemonetics Reports Double Digit Growth in Earnings for First Quarter Fiscal 2010 ; Company Affirms Full Year Guidance

Haemonetics Reports Double Digit Growth in Earnings for First Quarter Fiscal 2010

Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release: August 3, 2009

Battle Road Research Expands Healthcare Coverage and Launches Blog

Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology

Haemonetics Shares Success of Outstanding Fiscal 2009 Performance with Employees

Haemonetics Reports Strong Double Digit Growth in Revenue, Net Income, and EPS for Fiscal 2009 and Issues Guidance for Continued, Strong Growth in Fiscal 2010

Haemonetics Sets Date For Fourth Quarter Fiscal Year 2009 Earnings Release: May 4, 2009

Form 4 White Jonathan For: Oct 30 (10K)

Form 4 HAEMONETICS CORP For: Oct 30 Filed by: LOPEZ ALICIA R (10K)

Form 4 HAEMONETICS CORP For: Oct 30 Filed by: LINDOP CHRISTOPHER J (10K)

Form 4 HANLON SUSAN M For: Oct 30 (10K)

Form 4 ALLEN PETER M For: Oct 30 (10K)

Form 4 Gordon Mikael For: Oct 27 (10K)

Form 4 Gordon Mikael For: Oct 22 (10K)

Form 4 CONCANNON BRIAN For: Oct 27 (10K)

Form 4 ALLEN PETER M For: Oct 27 (10K)

Form 4 FORISH JOSEPH J For: Oct 27 (10K)